Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype

Journal of the American College of Cardiology

Volumn 37, Issue 7, 2001, Pages 1808-1812

  Cicoira, Mariantonietta ^a   Zanolla, Luisa ^a,b   Rossi, Andrea ^a   Golia, Giorgio ^a   Franceschini, Lorenzo ^a   Cabrini, Giulio ^b   Bonizzato, Alberto ^b   Graziani, Maristella ^b   Anker, Stefan D ^c,d   Coats, Andrew J S ^c   Zardini, Piero ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; NEUROHORMONE;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE INSERTION; GENOTYPE; HEART FAILURE; HORMONE RESPONSE; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT FAILURE;

ADULT; AGED; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; FEMALE; GENE DELETION; GENOTYPE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE;

EID: 0035369667     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01237-2     Document Type: Article

References (28)

1. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
2. Comparison of enalapril with idralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
3. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
4. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
5. The neurohormonal hypothesis: A theory to explain the mechanisms of disease progression in heart failure
6. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
7. Neurohormonal reactivation in heart failure patients on chronic ACAD inhibitor therapy: A longitudinal study
8. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?
9. Captopril in heart failure: A double-blind controlled trial
10. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone evaluation study investigators
11. An insertion/deletion polymorphism in the angiotensin-1 converting enzyme gene accounting for half the variance of serum enzyme levels
12. Angiotensin-converting enzyme in the human heart: Effect of the deletion/insertion polymorphism
13. Angiotensin-converting enzyme DD genotype in patients with ischemic or idiopathic dilated cardiomyopathy
14. The treatment of heart failure
15. Evidence from combined segregation and linkage that a variant of the angiotensin-I converting enzyme (ACE) gene controls plasma ACE levels
16. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material
17. Polymorphism of the angiotensin-converting enzyme gene in subjects who die from coronary heart disease
18. Does angiotensin-converting enzyme polymorphism influence the clinical manifestation and progression of heart failure in patients with dilated cardiomyopathy?
19. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial)
20. Captopril in heart failure: A double-bind controlled trial
21. Aldosterone escape during ACE inhibitor therapy in chronic heart failure
22. Familial resemblance of plasma angiotensin-converting enzyme level: The Nancy study
23. Angiotensin-converting enzyme in the human heart: Effect of the deletion/insertion polymorphism
24. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction
25. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure
26. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training
27. ACE (I/D) genotype as a predictor of the magnitude of the response to an ACE inhibitor drug (enalaprilat) in humans
28. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene in response to angiotensin-converting enzyme inhibitors in patients with heart failure